Biosion, Inc. Appoints Furqan Ahmed, Pharm D As Vice President and Head of Business Development
07/05/23, 2:14 PM
Location
nanjingIndustry
therapeutics
biotechnology
health care
Position
head of business development
Biosion, Inc. , a global, clinical-stage biotechnology company, today announced the appointment of Furqan Ahmed, PharmD., as the Vice President and Head of Business Development. In this position, Furqan will be responsible for all aspects of the company's global business development efforts to maximize the value of Biosion's platforms and innovative pipeline.
Company Info
Location
nanjing, jiangsu, china
Additional Info
Biosion is a global, clinical-stage biotechnology company committed to developing breakthrough antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases. Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived proprietary technologies including the H3 antibody discovery platform, SynTracer HT® endocytosis platform, and Flexibody® bispecific platform. Biosion's lead asset, BSI-045B (anti-TSLP mAb), is currently in phase-II for severe asthma and atopic dermatitis, with another 4 partnered assets in phase-I/II. Biosion and partners have plans to progress the immune-oncology and antibody drug conjugate-based portfolio into clinical trials for oncology indications over the next year. Biosion has operations in the US, Australia, and China.